ReNeuron Group plc (RNUGF)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 263 Thousand GBP | 232.91% |
| 2022 | 79 Thousand GBP | 100.85% |
| 2021 | -9.24 Million GBP | 9.97% |
| 2020 | -10.27 Million GBP | 36.59% |
| 2019 | -16.19 Million GBP | 2.51% |
| 2018 | -16.61 Million GBP | -13407.32% |
| 2017 | -123 Thousand GBP | -95.24% |
| 2016 | -63 Thousand GBP | 99.13% |
| 2015 | -7.22 Million GBP | -24.33% |
| 2014 | -5.8 Million GBP | -21.77% |
| 2013 | -4.76 Million GBP | -12022.5% |
| 2012 | 40 Thousand GBP | 37.93% |
| 2011 | 29 Thousand GBP | -6.45% |
| 2010 | 31 Thousand GBP | -66.67% |
| 2009 | 93 Thousand GBP | 244.44% |
| 2008 | 27 Thousand GBP | -44.9% |
| 2007 | 49 Thousand GBP | 444.44% |
| 2006 | 9000.00 GBP | 200.0% |
| 2005 | 3000.00 GBP | 200.0% |
| 2004 | 1000.00 GBP | -94.74% |
| 2003 | 19 Thousand GBP | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | -1.01 Million GBP | -2248.84% |
| 2024 Q2 | -1.01 Million GBP | 0.0% |
| 2023 FY | 263 Thousand GBP | 232.91% |
| 2023 Q4 | -43 Thousand GBP | 93.79% |
| 2023 Q2 | 306 Thousand GBP | 124.02% |
| 2023 Q1 | -1.27 Million GBP | -746.7% |
| 2023 Q3 | -692.5 Thousand GBP | -326.31% |
| 2022 Q4 | 197 Thousand GBP | 111.65% |
| 2022 Q3 | -1.69 Million GBP | -1333.47% |
| 2022 FY | 79 Thousand GBP | 100.85% |
| 2022 Q1 | -2.14 Million GBP | -36.81% |
| 2022 Q2 | -118 Thousand GBP | 94.49% |
| 2021 Q1 | -2.95 Million GBP | 16.17% |
| 2021 FY | -9.24 Million GBP | 9.97% |
| 2021 Q4 | -1.56 Million GBP | 6.46% |
| 2021 Q3 | -1.67 Million GBP | 42.89% |
| 2021 Q2 | -2.92 Million GBP | 0.69% |
| 2020 Q2 | 1.41 Million GBP | 190.42% |
| 2020 Q4 | -3.51 Million GBP | -0.01% |
| 2020 Q1 | -1.56 Million GBP | 62.75% |
| 2020 FY | -10.27 Million GBP | 36.59% |
| 2020 Q3 | -3.51 Million GBP | -348.39% |
| 2019 Q3 | -4.2 Million GBP | -64.44% |
| 2019 Q1 | -2.55 Million GBP | 28.81% |
| 2019 FY | -16.19 Million GBP | 2.51% |
| 2019 Q4 | -4.2 Million GBP | 0.0% |
| 2019 Q2 | -2.55 Million GBP | 0.0% |
| 2018 Q3 | -3.59 Million GBP | 16.21% |
| 2018 Q2 | -4.28 Million GBP | 0.0% |
| 2018 Q1 | -4.28 Million GBP | -36.2% |
| 2018 FY | -16.61 Million GBP | -13407.32% |
| 2018 Q4 | -3.59 Million GBP | 0.0% |
| 2017 Q2 | -3.93 Million GBP | 0.0% |
| 2017 FY | -123 Thousand GBP | -95.24% |
| 2017 Q1 | -3.93 Million GBP | -30.93% |
| 2017 Q3 | -3.14 Million GBP | 19.91% |
| 2017 Q4 | -3.14 Million GBP | 0.0% |
| 2016 Q1 | -1.85 Million GBP | -25.08% |
| 2016 FY | -63 Thousand GBP | 99.13% |
| 2016 Q4 | -3 Million GBP | 0.0% |
| 2016 Q3 | -3 Million GBP | -62.05% |
| 2016 Q2 | -1.85 Million GBP | 0.0% |
| 2015 Q1 | -1.86 Million GBP | -55.99% |
| 2015 Q4 | -1.48 Million GBP | 0.0% |
| 2015 Q3 | -1.48 Million GBP | 20.78% |
| 2015 Q2 | -1.86 Million GBP | 0.0% |
| 2015 FY | -7.22 Million GBP | -24.33% |
| 2014 Q1 | -1.37 Million GBP | 42.52% |
| 2014 FY | -5.8 Million GBP | -21.77% |
| 2014 Q4 | -1.19 Million GBP | 0.0% |
| 2014 Q3 | -1.19 Million GBP | 12.77% |
| 2014 Q2 | -1.37 Million GBP | 0.0% |
| 2013 Q4 | -2.39 Million GBP | 0.0% |
| 2013 Q3 | -2.39 Million GBP | 0.0% |
| 2013 FY | -4.76 Million GBP | -12022.5% |
| 2012 FY | 40 Thousand GBP | 37.93% |
| 2011 FY | 29 Thousand GBP | -6.45% |
| 2010 FY | 31 Thousand GBP | -66.67% |
| 2009 FY | 93 Thousand GBP | 244.44% |
| 2008 FY | 27 Thousand GBP | -44.9% |
| 2007 FY | 49 Thousand GBP | 444.44% |
| 2006 FY | 9000.00 GBP | 200.0% |
| 2005 FY | 3000.00 GBP | 200.0% |
| 2004 FY | 1000.00 GBP | -94.74% |
| 2003 FY | 19 Thousand GBP | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -242.622% |
| CSL Limited | 7.56 Billion USD | 99.997% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 98.247% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -8378.401% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 97.753% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 99.779% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 870.132% |
| Mesoblast Limited | -35.16 Million USD | 100.748% |
| Marizyme, Inc. | 457.7 Thousand USD | 42.539% |
| Genus plc | 178.7 Million USD | 99.853% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | 35.879% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 2490.909% |
| ContraFect Corporation | -154 Thousand USD | 270.779% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 626.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| IMV Inc. | -962.29 Thousand USD | 127.33% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 167.871% |
| MultiCell Technologies, Inc. | 49.32 USD | -533152.23% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 99.347% |
| EV Biologics, Inc. | 48.9 Thousand USD | -437.832% |
| Q BioMed Inc. | -8988.00 USD | 3026.124% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 99.069% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 1805.135% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -275.714% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 311.668% |
| SQZ Biotechnologies Company | 9.79 Million USD | 97.315% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 5410.985% |
| Arch Therapeutics, Inc. | -2439.00 USD | 10883.108% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -300.134% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | -87.189% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 99.881% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | -322.653% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 369.702% |
| GB Sciences, Inc. | -624.00 USD | 42247.436% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 405.714% |
| argenx SE | 1.1 Billion USD | 99.976% |
| HST Global, Inc. | - USD | -Infinity% |
| Halberd Corporation | -208.00 USD | 126542.308% |
| Enzolytics Inc. | 30.7 Thousand USD | -756.454% |
| Resverlogix Corp. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | 45.485% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 101.019% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 99.407% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 123.038% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 151.117% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | 57.401% |
| ONE Bio Corp. | 20.12 Million USD | 98.693% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 99.936% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 3069.738% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 413.659% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Agentix Corp. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Kadimastem Ltd | -630.13 Thousand USD | 141.737% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | 73.38% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 97.264% |
| BioStem Technologies, Inc. | 15.42 Million USD | 98.295% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 2322.222% |
| Cell Source, Inc. | - USD | -Infinity% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 644.976% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -48.958% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -48.958% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | 1.35 Million USD | 80.621% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 1006.897% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | 41.561% |
| SYBLEU INC | 11.69 Thousand USD | -2148.632% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 182.314% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 94.293% |
| Bioxytran, Inc. | -8285.00 USD | 3274.412% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 170.509% |
| Neutra Corp. | 14.33 Thousand USD | -1734.67% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 420.732% |
| PureTech Health plc | -1.6 Million USD | 116.407% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 126.268% |
| IXICO plc | 3.27 Million USD | 91.957% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 137.896% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 114.685% |
| CSL Limited | 7.7 Billion USD | 99.997% |
| Cellectis S.A. | 18 Thousand USD | -1361.111% |